Literature DB >> 15147348

Differential expression of CTLA-4 among T cell subsets.

C B Jago1, J Yates, N Olsen Saraiva Câmara, R I Lechler, G Lombardi.   

Abstract

CTLA-4 (CD152), the CD28 homologue, is a costimulatory molecule with negative effects on T cell activation. In addition to its role in the termination of activation, CTLA-4 has been implicated in anergy induction and the function of regulatory cells. As an intracellular molecule, it must first relocate to the cell surface and be ligated, in order to inhibit activation. Although some studies have investigated CTLA-4 expression on CD4(+) T cells, evidence is lacking regarding the kinetics of expression, and expression on T cell subpopulations. We have investigated CTLA-4 kinetics on human purified peripheral CD4(+), naïve, memory, CD4(+)CD25(-), CD4(+)CD25(+) regulatory T cells, and T cell clones. Intracellular stores of CTLA-4 were shown to be very low in naïve T cells, whilst significant amounts were present in memory T cells and T cell clones. Cell surface CTLA-4 expression was then investigated on CD4(+)CD45RA(+) (naïve), CD4(+)CD45RO(+) (memory), CD4(+)CD25(-), and CD4(+)CD25(+) T cells. CD25 and CD45RO are both expressed by regulatory T cells. On naïve and CD4(+)CD25(-) T cells, CTLA-4 expression declined after four hours. In contrast, on memory and CD4(+)CD25(+) T cells, high levels of expression were maintained until at least 48 hours. In addition, significant CTLA-4 expression was observed on T cell clones following anergy induction, indicating the potential involvement of CTLA-4 also in this form of tolerance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15147348      PMCID: PMC1809051          DOI: 10.1111/j.1365-2249.2004.02478.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  31 in total

1.  Structural analysis of CTLA-4 function in vivo.

Authors:  E L Masteller; E Chuang; A C Mullen; S L Reiner; C B Thompson
Journal:  J Immunol       Date:  2000-05-15       Impact factor: 5.422

Review 2.  CD28, CTLA-4 and their ligands: who does what and to whom?

Authors:  D M Sansom
Journal:  Immunology       Date:  2000-10       Impact factor: 7.397

3.  CTLA-4 blockade of antigen-induced cell death.

Authors:  S da Rocha Dias; C E Rudd
Journal:  Blood       Date:  2001-02-15       Impact factor: 22.113

4.  Complete sequence determination of the mouse and human CTLA4 gene loci: cross-species DNA sequence similarity beyond exon borders.

Authors:  V Ling; P W Wu; H F Finnerty; A H Sharpe; G S Gray; M Collins
Journal:  Genomics       Date:  1999-09-15       Impact factor: 5.736

5.  Regulation of surface and intracellular expression of CTLA-4 on human peripheral T cells.

Authors:  X B Wang; C Y Zheng; R Giscombe; A K Lefvert
Journal:  Scand J Immunol       Date:  2001-11       Impact factor: 3.487

Review 6.  CD4+ CD25+ suppressor T cells: more questions than answers.

Authors:  Ethan M Shevach
Journal:  Nat Rev Immunol       Date:  2002-06       Impact factor: 53.106

7.  Antigen-specific T cell suppression by human CD4+CD25+ regulatory T cells.

Authors:  Leonie S Taams; Milica Vukmanovic-Stejic; Jay Smith; Padraic J Dunne; Jean M Fletcher; Fiona J Plunkett; Saskia B Ebeling; Giovanna Lombardi; Malcolm H Rustin; Johannes W J Bijlsma; Floris P J G Lafeber; Mike Salmon; Arne N Akbar
Journal:  Eur J Immunol       Date:  2002-06       Impact factor: 5.532

8.  Cytotoxic T lymphocyte antigen 4 and CD28 modulate cell surface raft expression in their regulation of T cell function.

Authors:  M Martin; H Schneider; A Azouz; C E Rudd
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307

9.  Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.

Authors:  T Takahashi; T Tagami; S Yamazaki; T Uede; J Shimizu; N Sakaguchi; T W Mak; S Sakaguchi
Journal:  J Exp Med       Date:  2000-07-17       Impact factor: 14.307

10.  Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin.

Authors:  J R Lamb; B J Skidmore; N Green; J M Chiller; M Feldmann
Journal:  J Exp Med       Date:  1983-05-01       Impact factor: 14.307

View more
  65 in total

1.  IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation.

Authors:  Anushruti Sarvaria; Rafet Basar; Rohtesh S Mehta; Hila Shaim; Muharrem Muftuoglu; Ahmad Khoder; Takuye Sekine; Elif Gokdemir; Kayo Kondo; David Marin; May Daher; Amin M Alousi; Abdullah Alsuliman; Enli Liu; Betul Oran; Amanda Olson; Roy B Jones; Uday Popat; Chitra Hosing; Richard Champlin; Elizabeth J Shpall; Katayoun Rezvani
Journal:  Blood       Date:  2016-07-20       Impact factor: 22.113

Review 2.  New Strategies in Bladder Cancer: A Second Coming for Immunotherapy.

Authors:  Ali Ghasemzadeh; Trinity J Bivalacqua; Noah M Hahn; Charles G Drake
Journal:  Clin Cancer Res       Date:  2015-12-18       Impact factor: 12.531

Review 3.  A review of the importance of immune responses in luminal B breast cancer.

Authors:  Delia J Nelson; Briony Clark; Kylie Munyard; Vincent Williams; David Groth; Jespal Gill; Henry Preston; Arlene Chan
Journal:  Oncoimmunology       Date:  2017-01-19       Impact factor: 8.110

Review 4.  Is there a room for immune checkpoint inhibitors in early stage non-small cell lung cancer?

Authors:  Elisa Gobbini; Matteo Giaj Levra
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

5.  Nonapoptotic and extracellular activity of granzyme B mediates resistance to regulatory T cell (Treg) suppression by HLA-DR-CD25hiCD127lo Tregs in multiple sclerosis and in response to IL-6.

Authors:  Siddheshvar Bhela; Christine Kempsell; Monali Manohar; Margarita Dominguez-Villar; Russell Griffin; Pooja Bhatt; Pia Kivisakk-Webb; Robert Fuhlbrigge; Thomas Kupper; Howard Weiner; Clare Baecher-Allan
Journal:  J Immunol       Date:  2015-01-30       Impact factor: 5.422

Review 6.  Challenges and opportunities in targeting the CD28/CTLA-4 pathway in transplantation and autoimmunity.

Authors:  Rebecca L Crepeau; Mandy L Ford
Journal:  Expert Opin Biol Ther       Date:  2017-05-30       Impact factor: 4.388

Review 7.  The role of FOXP3+ regulatory T cells in human autoimmune and inflammatory diseases.

Authors:  A Mohr; M Atif; R Balderas; G Gorochov; M Miyara
Journal:  Clin Exp Immunol       Date:  2019-03-24       Impact factor: 4.330

8.  Identification of susceptibility SNPs in CTLA-4 and PTPN22 for scleritis in Han Chinese.

Authors:  F Li; X Ma; L Du; L Shi; Q Cao; N Li; T Pang; Y Liu; A Kijlstra; P Yang
Journal:  Clin Exp Immunol       Date:  2019-04-16       Impact factor: 4.330

Review 9.  Can peripheral leukocytes be used as Alzheimer's disease biomarkers?

Authors:  Kavon Rezai-Zadeh; David Gate; Christine A Szekely; Terrence Town
Journal:  Expert Rev Neurother       Date:  2009-11       Impact factor: 4.618

10.  Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti-CTLA-4 Antibodies Induces Tumor Shrinkage In Vivo.

Authors:  Elizabeth K Duperret; Aspen Trautz; Regina Stoltz; Ami Patel; Megan C Wise; Alfredo Perales-Puchalt; Trevor Smith; Kate E Broderick; Emma Masteller; J Joseph Kim; Laurent Humeau; Kar Muthumani; David B Weiner
Journal:  Cancer Res       Date:  2018-10-04       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.